AWE
NTLA icon

Avidian Wealth Enterprises’s Intellia Therapeutics NTLA Stock Holding History

Avidian Wealth Enterprises’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,600
Closed -$369K – 463
2022
Q3 		$369K Buy
+6,600
New +$409K 0.03% 279
2022
Q1 		– Sell
-1,700
Closed -$201K – 552
2021
Q4 		$201K Buy
+1,700
New +$213K 0.01% 495

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Avidian Wealth Enterprises's NTLA Position: Q4 2022 in Review

Avidian Wealth Enterprises sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 6,600 shares — an estimated $369K sold.

Avidian Wealth Enterprises first reported a position in NTLA in Q4 2021 and held it in 2 quarters. The position peaked at $369K in Q3 2022. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Avidian Wealth Enterprises reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Avidian Wealth Enterprises sold 6,600 Intellia Therapeutics shares in Q4 2022, an estimated $369K.
  • Avidian Wealth Enterprises first reported a position in Intellia Therapeutics in Q4 2021 and held it in 2 quarters.
  • Avidian Wealth Enterprises's Intellia Therapeutics position peaked at $369K in Q3 2022.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Avidian Wealth Enterprises's 13F filing for Q4 2022, filed 6 Feb 2023.